Aidoc
Clinical AI platform for radiology and enterprise imaging workflows.
Last updated: June 5, 2026
Back to directoryFDA-cleared point-of-care fluorescence wound imaging device platform that helps clinicians visualize bacterial fluorescence and measure wounds.
Wound care teams that need adjunctive information about bacterial burden and wound measurements during clinician-reviewed wound assessment.
Compare within workflow: Medical imaging and radiology · comparison shortlist · source index
Product-specific review. These product-specific signals summarize what the cited sources imply before treating MolecuLight as safe for a local clinical, operational, or research workflow.
| Regulatory / FDA | Match the device model and intended use to FDA-cleared indications and avoid treating fluorescence as a standalone infection diagnosis. |
|---|---|
| Privacy | Review image transfer, Wi-Fi, local device storage, EHR integration, HIPAA/SOC 2 materials, user controls, and retention. |
| Evidence | Assess clinical studies, detection limitations, false negatives from blood or workflow issues, impact on antimicrobial use, and local wound-care outcomes. |
| Workflow | Best used as adjunctive imaging during wound assessment with training, room setup, interpretation rules, documentation, and escalation pathways. |
MolecuLight describes its i:X and DX devices as FDA-cleared Class II point-of-care fluorescence wound imaging tools for detecting regions associated with elevated bacterial loads, measuring wounds, and supporting wound management.
Not for: Standalone infection diagnosis, replacing clinical signs, culture decisions, debridement judgment, or use without dark-room and interpretation workflow controls.
Use these links to confirm current claims, terms, regulatory status, pricing, and deployment requirements.